Posted by Michael Rae on October 1, 2014 | Chief Science Officer's Team

Rejuvenation of the aging brain will require the integrated application of several core rejuvenation biotechnologies, including notably those that remove intra- and extraneuronal aggregates implicated in neurodegenerative aging and mature cell therapy. Numerous aggregate-clearing rejuvenation biotechnologies are now in human trials, whereas mature cell therapy for the brain is a more challenging goal and will not be available for some time. In this context, an alternative approach to maintaining the viability of aging neurons could complement aggregate-clearing therapies to preserve neurons until neural replacement and reinforcement matures. In this post we explore the potential of one recently-emerged approach: inhibition of the unfolded protein response (UPR).

Posted by Mike Kope, CEO on September 4, 2014 | Outreach

Reuter's announced today the launch of a Calico/Abbvie agreement. SENS Research Foundation congratulates U.S. drugmaker AbbVie Inc and Calico on the excellent news of their collaboration.